Basak, S. "Sun Pharma Recalls 400,000 Bottles of Drugs in U.S., FDA Says," Bloomberg News, May 8, 2014.
India's largest drug manufacturer Sun Pharmaceutical Industries Ltd., is recalling nearly 400,000 bottles of its generic form of the anti-depressant Effexor (Venlafaxine) and the antihistamine Cetirizine because the pills fail to dissolve properly.
 Basak, S. "Sun Pharma Recalls 400,000 Bottles of Drugs in U.S., FDA Says," Bloomberg News, May 8, 2014.
The FDA has approved Merck & Co's new drug Ragwitek for the treatment of short ragweed pollen allergies for adults aged 18 to 65. Ragwitek contains an extract from short ragweed (Ambrosia artemisiifolia) pollen and is administered sublingually as a dissolving tablet. Treatment with Ragwitek is started 12 weeks before the start of ragweed pollen season and continued throughout the season. The first dose is taken in a health care professional’s office where the patient is to be observed for at least 30 minutes for potential adverse reactions. After the first dose, patients can take Ragwitek at home.
 FDA News Release, "FDA approves Ragwitek for short ragweed pollen allergies," April 17, 2014.
The FDA has approved Merck & Co's new drug Grastek for the treatment of grass pollen allergies for patients age 5 to 65. Grastek is an immunotherapy treatment designed to boost the immune system and make it less sensitive to allergens. The FDA advisory committee that unanimously recommended approval of the drug also called for post-approval studies in children, citing side effects such as lip swelling, throat irritation and oral blistering. The drug has been available in Europe since 2006 under the name Grazax.
 Reuters, "Merck's grass pollen allergy drug wins U.S. approval," April 14, 2014.